© 2021 MJH Life Sciences and Neurology Live. All rights reserved.
© 2021 MJH Life Sciences™ and Neurology Live. All rights reserved.
June 19, 2021
Neurology News Network for the week ending June 19, 2021.
June 18, 2021
Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 18, 2021.
The median time from randomization to atrial fibrillation detection was 99 days in the cardiac monitor group compared to 181 days for the control group.
With new formulations of effective seizure rescue medications available, epilepsy specialists have begun to refine the approach and education to treating these emergency situations.
The medical director of the Ohio State Sleep Medicine Institute discussed the effect of FT218 in treating narcolepsy regardless of stimulant use, as well as its weight-related benefits it brings.
"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Michael J. Thorpy, MD.
June 17, 2021
While the relationship between sleep and cognition needs to be further studied, sleep-based interventions may be a future approach to help prevent cognitive decline.
Biogen’s investigational antibody against the N-terminus of tau failed to meet any of the efficacy or exploratory end points in individuals with mild cognitive impairment or mild Alzheimer disease.
The director of the Headache Center of Southern California discussed research opportunities for layered treatment approaches in migraine.
Primary and secondary end points of the trial will assess safety and both cognitive and functional efficacy, measured through ADAS-Cog, ADCS-ADL, and CDR-SB.